Safety of recombinant zoster vaccine for the treatment of immune-mediated inflammatory diseases

Summaries 3 min 587

Font Size

Created On: 31/03/2021

Safety of recombinant zoster vaccine for the treatment of immune-mediated inflammatory diseases

A retrospective study was performed to explore the safety of recombinant zoster vaccine in individuals suffering from IMID.

See All

Key take away

Administration of recombinant zoster vaccine in immune-mediated inflammatory diseases (IMID) individuals was generally well-tolerated. However, in the first 12 weeks following vaccination, mild flares were not uncommon.

Background

A retrospective study was performed to explore the safety of recombinant zoster vaccine in individuals suffering from IMID.

Method

Participants who were given recombinant zoster vaccine in a single-center rheumatology department were retrospectively incorporated. The IMID flare was characterized as (i) flare documentation in the office notes or participant portal communication or (ii) novel prescription of prednisone in the 12 weeks after each dose.

Result

In total, 622 patients were incorporated (median age 67 years), 8.5% of them witnessed adverse events and Herpes Zoster incidence was 0.6% following the median follow-up of about 36 weeks. Of 359 IMID subjects: 88 had rheumatoid arthritis (25%), 50 vasculitis (14%), 29 polymyalgia rheumatica (8%). At the vaccination, 35% were on glucocorticoids. In total, 59 subjects (16%) witnessed a flare, 18 flares took place in temporal relation to a therapy alteration (31%).

Rheumatoid arthritis subjects had the greatest flare rate (n = 21, 24%). Notably, 25% of subjects who flared needed adjustment of immunosuppression. In a multivariate assessment, the usage of glucocorticoids at vaccination time was linked with flare after vaccination (Odds ratio 2.31 [1.3-4.1]). A time-to-flare survival assessment (Cox-model) demonstrated that glucocorticoids were an important predictor of IMID flare following the initial recombinant zoster vaccine dose (Hazard ratio 2.4 [1.3-4.5]) and that a flare following the initial dose was linked with flaring after the second recombinant zoster vaccine dose (Hazard ratio 3.9 [1.7-9]).